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5-Fluorouracil (5-FU), a chemotherapeutic drug commonly used in cancer treatment, imbalances nucleotide pools,
thereby favoring misincorporation of uracil and 5-FU into genomic DNA. The processing of these bases by DNA repair
activities was proposed to cause DNA-directed cytotoxicity, but the underlying mechanisms have not been resolved. In
this study, we investigated a possible role of thymine DNA glycosylase (TDG), one of four mammalian uracil DNA
glycosylases (UDGs), in the cellular response to 5-FU. Using genetic and biochemical tools, we found that inactivation
of TDG significantly increases resistance of both mouse and human cancer cells towards 5-FU. We show that excision of
DNA-incorporated 5-FU by TDG generates persistent DNA strand breaks, delays S-phase progression, and activates
DNA damage signaling, and that the repair of 5-FU–induced DNA strand breaks is more efficient in the absence of TDG.
Hence, excision of 5-FU by TDG, but not by other UDGs (UNG2 and SMUG1), prevents efficient downstream processing
of the repair intermediate, thereby mediating DNA-directed cytotoxicity. The status of TDG expression in a cancer is
therefore likely to determine its response to 5-FU–based chemotherapy.
Citation: Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, et al. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS
Biol 7(4): e1000091. doi:10.1371/journal.pbio.1000091
Introduction
The antimetabolite 5-ﬂuorouracil (5-FU) is an analog of
uracil with a ﬂuorine substitution at the C5 position.
Developed as an inhibitor of thymidylate synthase (TS) [1],
it has become an important compound in the ﬁrst-line
treatment of a range of human cancers, most prominently
colorectal carcinomas [2]. Inside cells, 5-FU is converted to
different active metabolites, including ﬂuorodeoxyuridine
monophosphate (FdUMP), ﬂuorodeoxyuridine triphosphate
(FdUTP), and ﬂuorouridine triphosphate (FUTP) [2]. These
metabolites have been implicated in both global RNA
metabolism due to incorporation of the ribonucleotide
FUMP into RNA, and DNA metabolism due to TS inhibition
or direct incorporation of FdUMP into DNA. The therapeutic
importance of its DNA-directed action is emphasized by a
direct correlation of TS activity with the response rate of
tumors or cancer cell lines to the treatment with 5-FU [3–5].
TS converts deoxyuridine monophosphate (dUMP) to deox-
ythymidine monophosphate (dTMP). FdUMP inactivates TS
irreversibly upon docking to its nucleotide binding site and
forming a stable complex with the cofactor 5,10-methylene-
tetrahydrofolate [6,7]. Thus, TS inhibition deprives the cell of
the capacity to synthesize dTMP from dUMP and, thereby,
elevates deoxyuridine triphosphate (dUTP) levels at the
expense of deoxythymidine triphosphate (dTTP). The result-
ing dUTP/dTTP imbalance then favors the misincorporation
of dUMP during DNA replication, giving rise to a dose-
dependent increase in the steady-state level of DNA uracil
[8,9].
It has been argued that the therapeutic effects of TS
inhibition are based on the fragmentation of genomic DNA
as a result of massive uracil excision by the replication-
associated uracil DNA glycosylase (UDG) UNG2 connected
with futile cycles of base excision repair (BER) [2,10,11].
Although UNG2 expression may be affected in human cells
treated with ﬂuorodeoxyuridine [12], such a scenario is not
entirely consistent with other available experimental evi-
dence. UNG2 clearly constitutes a major activity against the
accumulation of uracil in genomic DNA [13], but its
expression status does not affect the cellular resistance
towards TS inhibition [14] and, hence, the survival of 5-FU–
treated cells [15]. Thus, uracil excision by UNG2 is not likely
to account for the DNA-directed cytotoxicity of 5-FU. In light
of a recent report, however, showing that FdUMP gets itself
incorporated into genomic DNA in 5-FU–treated cells, with
levels even exceeding those of misincorporated uracil [9], it
can be argued that the 5-FU rather than the uracil in the DNA
is the cell toxic lesion.
Although UNG is the most efﬁcient and speciﬁc UDG
present in mammalian cells, it is not the only one. Single-
strand–selective monofunctional uracil-DNA glycosylase 1
(Smug1) [16], thymine DNA glycosylase (TDG) [17], and
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methyl-CpG binding domain protein 4 (MBD4) [18,19]
represent additional activities. All these enzymes are capable
of processing uracil, as well as 5-FU, in DNA, albeit with
different kinetic properties. Smug1 was shown to provide
resistance to 5-FU–exposed cells [9], whereas MBD4 may
contribute to the toxicity of the drug, arguably through DNA
damage signaling [20]. Human TDG, originally discovered as a
GT mismatch-speciﬁc thymine DNA glycosylase [21], pro-
cesses a broad range of substrates, including uracil and 5-FU.
Although it has a strong preference for bases mispaired with a
guanine, TDG excises 5-FU with a high efﬁciency, irrespective
of whether the opposite base is a guanine or an adenine
[17,22,23]. Consistently, plasmid-based in vitro repair assays
with cell lysates have revealed a signiﬁcant contribution of
TDG to 5-FU excision [24].
Due to the redundancy of UDG activities that can
contribute to 5-FU processing in cells, it is difﬁcult to predict
in which way and to what extent one or the other contributes
to the cellular response to 5-FU, and thus to the efﬁcacy of
cancer therapies including 5-FU. Moreover, recent evidence
from in vitro repair studies has implicated the postreplicative
mismatch repair (MMR) system in the processing of 5-FUG
base pairs [24]. In part, this accounts for the increased
resistance of MMR-deﬁcient cells to treatment with ﬂuoro-
pyrimidines [25–27]. Given the general nucleotide imbalance
induced by TS inhibition, however, the MMR-dependent
toxicity of 5-FU is best explained by excessive formation and
repair of DNA mispairs during replication [26,28]. Hence, the
DNA-directed effects of 5-FU may reﬂect two lines of
responses: the excision of 5-FU or U from DNA (5-FU/UA,
5-FU/UG) mainly by UDGs, and the excision of mismatched
nucleotides mainly by MMR.
The objective of this study was to clarify the role of TDG in
this context. We examined cellular and molecular responses
to 5-FU exposure of matched Tdg-proﬁcient and -deﬁcient
mouse embryonic ﬁbroblasts and stem cells, as well as human
HeLa cells. We show that TDG, of all UDGs, is responsible for
the accumulation of DNA strand breaks, a delay in S-phase
progression, and a persistent activation of DNA damage
signaling upon treatment of cells with 5-FU, and that
inactivation of Tdg by mutation causes resistance towards
the drug. We conclude that TDG, unlike UNG2 and Smug1,
mediates the DNA-directed cytotoxic effects of 5-FU.
Results
TDG Deficiency Confers Resistance towards 5-FU
To investigate the role of TDG during 5-FU treatment of
cells in culture, we established SV40 immortalized mouse
embryonic ﬁbroblasts (MEFs) with homozygous or hetero-
zygous Tdg disruptions (Tdgþ/þ, Tdgþ/, Tdg/) from embryos
(embryonic day [ED] 9.5) of heterozygous matings. The Tdg
knockout allele, generated by classical gene targeting, had a
replacement of exons 6 and 7, encoding parts of the catalytic
core of TDG, with a neomycin resistance cassette (Figure S1).
We then used litter-matched MEF lines for phenotypic
examination. Western blotting with a polyclonal anti-mouse
TDG antibody conﬁrmed that neither full-length nor
truncated versions of TDG were present in whole-cell extracts
of the homozygous knockout MEFs, whereas heterozygous
cells produced about half endogenous levels of the protein
(Figure 1A; unpublished data). Continuous exposure of these
MEFs to 5-FU for 48 h reduced living cell counts in a dose-
dependent manner. However, compared to wild-type MEFs,
TDG-deﬁcient cells displayed a remarkable resistance (Figure
1B), and heterozygous cells showed an intermediate 5-FU
sensitivity (Figure S2). These ﬁndings implicated a rate-
limiting contribution of TDG to 5-FU–mediated cytotoxicity.
A differential response of TDG-proﬁcient and -deﬁcient
MEFs to 5-FU treatment was also observed in a real-time
assessment of growth behavior. Whereas the cell numbers in
cultures of TDG-proﬁcient MEFs started to decline after 36 h
of 5-FU exposure, TDG-deﬁcient cells responded with a dose-
dependent growth retardation only (Figure 2A).
Since immortalization by the SV40 large-T antigen (LTA)
occurs through inactivation of antiproliferative proteins such
as p53 or pRb and, thus, can affect the cellular DNA damage
response [29,30], we also included spontaneously immortal-
ized MEF cell lines in our analysis. To this end, we set up
isogenic Tdg-proﬁcient and -deﬁcient MEF lines by stable
transfection of a single clone with either a complementing
Tdg transgene under the control of an SV40 promoter or the
corresponding expression vector only (Figure 1A). Survival
tests then showed that Tdg expression sensitized the Tdg-
deﬁcient cells to 5-FU to a level observed with the Tdg-
proﬁcient MEFs (Figure 1B). This conﬁrmed that the 5-FU
resistance of Tdg knockout cells is a direct consequence of the
loss of TDG rather than of unspeciﬁc effects by SV40 LTA
immortalization or other differences in clonal backgrounds.
To validate the resistance phenotype in cells that are
naturally immortal, we examined the 5-FU response of Tdgþ/
and Tdg/mouse embryonic stem (ES) cells generated in our
laboratory (Figure 1A) (Y. Saito, unpublished data). Also
there, the loss of TDG was associated with a remarkable
increase in resistance towards 5-FU (Figure 1B). Hence, the
mechanism by which TDG mediates cytotoxicity of 5-FU is
active in very divergent cell types, including immortalized
differentiated cells as well as undifferentiated stem cells.
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Author Summary
5-Fluorouracil (5-FU) has been used in clinical cancer therapy for
more than four decades. Despite a moderate response rate and a
high propensity of tumors to develop resistance to the drug, 5-FU
remains a mainstay in the first-line treatment of colorectal cancer in
particular. But precisely how 5-FU kills cancerous cells is not well
understood. It is known, for example, that 5-FU affects RNA or DNA
metabolism. Its DNA-directed cytotoxicity is thought to be based on
extensive misincorporation of uracil and 5-FU into cellular DNA, and
it has been proposed that the excision of these bases by uracil DNA
glycosylases (UDGs) results in destructive DNA fragmentation, which
can ultimately lead to cell death. However, the UDG responsible has
not been identified. We now show that inactivation of only one of
four mammalian UDGs, the thymine DNA glycosylase (TDG) in
mouse and human cells is sufficient to confer resistance to 5-FU,
whereas overexpression of TDG sensitizes cells to the drug. We
provide further experimental evidence to show that excision of 5-FU
from DNA by TDG, but not by other UDGs, inhibits efficient
downstream processing of the lesion. This leads to an accumulation
of DNA repair intermediates, which induce DNA damage signaling
and, eventually, cell death. Thus, TDG activity in cells represents an
important determinant of the DNA-directed cytotoxicity of 5-FU, an
observation that might help us to understand the variable response
to 5-FU treatments in cancer.
To examine the drug speciﬁcity of this phenotype, we
assessed the sensitivities of TDG-proﬁcient and -deﬁcient
MEFs towards the monofunctional DNA alkylating agent
methyl methansulfonate (MMS) (Figure 1C). At MMS concen-
trations yielding 10% cell survival, the TDG status did not
signiﬁcantly affect cellular sensitivity. At higher concentra-
tions (5% survival), however, TDG-deﬁcient cells were
slightly more sensitive. Thus, TDG may contribute to the
repair of MMS-induced DNA lesions, but it does not mediate
cytotoxicity as it does in the case of 5-FU.
Finally, to address the impact of TDG on long-term survival
of 5-FU–treated human cancer cells, we performed clono-
genic survival assays. We established HeLa cell clones either
stably transfected with a construct overexpressing human
TDG from a cytomegalovirus (CMV) promoter or with the
corresponding vector only. In addition, we applied a small
interfering RNA (siRNA) approach to knockdown TDG in
both HeLa cell clones. Continuous exposure of these HeLa
cells to 5-FU for 72 h reduced colony forming units in a dose-
dependent manner. The cellular sensitivity, however, signiﬁ-
cantly correlated with TDG protein levels (Figure 2B), being
highest for TDG-overexpressing cells and lowest for the
vector control cells with additional TDG knockdown. Thus,
reduced TDG expression confers a long-term survival beneﬁt
to HeLa cells, establishing that the TDG expression status in a
human cancer cell line determines its response to treatment
with 5-FU.
TDG Contributes to A5-FU Repair in Nuclear Extracts
Biochemical studies revealed that the human TDG acts on a
rather broad range of substrates, including GU and G5-FU
mispairs, but also 5-FU base-paired with adenine. 5-FU, in
fact, turned out to be the only base that is efﬁciently
processed by TDG in the normal base-pairing conﬁguration
or even in single-stranded DNA [22,23]. We thus reasoned
that the excision of 5-FU and/or uracil from genomic DNA by
TDG might be a source of 5-FU–mediated cytotoxicity in
TDG-proﬁcient cells. To test this, we ﬁrst validated the 5-FU–
and uracil-processing abilities of puriﬁed mouse TDG in
base-release assays. This showed that, like its human counter-
part, the mouse protein excises thymine, uracil, and 5-FU
opposite guanine, but also 5-FU paired with adenine, all with
comparable efﬁciencies (Figure 3A). AU containing homo-
duplex DNA, however, was hardly processed, suggesting that
TDG does not contribute signiﬁcantly to the repair of AU
base pairs.
Figure 1. TDG-Deficient Mouse Cells Are Resistant to 5-FU
(A) Western blot analysis of whole-cell protein extracts derived from SV40 immortalized MEFs (left), spontaneously immortalized MEFs (middle), and ES
cell lines (right) used. Tdg genotypes are as indicated. A highly specific polyclonal anti-mouse TDG antibody (TDGab) was used to detect TDG; beta-actin
staining served as loading control (b-actab). TDG is undetectable in extracts from Tdg
/ cells and reduced in heterozygous MEFs. Stable transfection of a
Tdg expression construct (pTdg) restores TDG levels in knockout MEFs.
(B) TDG-deficient MEF and ES cells exhibit increased 5-FU resistance, and ectopic expression of wild-type Tdg in knockout MEFs restores 5-FU sensitivity.
The sensitivity to increasing amounts of 5-FU was measured for the different cell lines after a continuous treatment of 48 h. Shown are survival curves as
percentages of mock-treated cells.
(C) TDG-deficient MEFs are not generally resistant to induced DNA base damage. Sensitivity to MMS was measured after a treatment for 1 h with
increasing concentrations of MMS. Shown are survival curves as percentages of mock-treated cells.
Shown are means 6 standard error of the mean (SEM) from at least three independent experiments. pC, vector control; pTdg, Tdg-expressing vector.
doi:10.1371/journal.pbio.1000091.g001
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To assess the contribution of the endogenous mouse TDG
to overall uracil and 5-FU processing, we then analyzed the
activities present in nuclear extracts of Tdg wild-type,
heterozygous, and null mutant MEFs. GT processing served
as a control and was detectable in extracts from wild-type, but
not from homozygous Tdg knockout cells (Figure 3A).
Compared to homozygous wild-type cells, heterozygous Tdg
knockout cells showed reduced thymine excision activity,
consistent with the reduced levels of TDG in these cells
(Figures 3B and 1A). Thus, TDG constitutes the major and
rate-limiting mismatch-speciﬁc thymine excision activity in
these cells, suggesting that MBD4, another GT processing
DNA glycosylase [31,32], is not or only poorly active. A lack of
MBD4 activity was observed also with protein extracts from
mouse ES cells (Y. Saito, unpublished data) and in previous
studies with different cell systems [24,33]. Considerably
higher amounts of nicked DNA products were detected for
all uracil- and 5-FU–containing substrates. Removal of uracil
and 5-FU from GU, G5-FU, and AU was equally efﬁcient
irrespective of the TDG status. Excision of 5-FU from an A5-
FU substrate, however, was signiﬁcantly reduced in extracts
from Tdg/MEFs (Figure 3A and 3B). The remaining activity
on A5-FU, but also the efﬁcient processing of AU, GU, and
GFU in extracts from Tdg knockout MEFs most likely reﬂects
the action of other UDGs with overlapping substrate spectra.
As the highly efﬁcient UNG2 was inhibited by addition of
saturating amounts of UGI peptide in these assays (unpub-
lished data) and MBD4 activity was not detected, Smug1 most
likely represents the redundant uracil- and 5-FU–processing
activity observed here. The data therefore suggest that, under
conditions of low UNG2 activity in cells, such as outside of S-
Figure 2. TDG-Induced Cell Death upon 5-FU Treatment
(A) Exposure to 5-FU results in death of TDG-proficient cells (Tdgþ/þ), but slow growth of TDG-deficient (Tdg/) cells. The growth of TDG wild-type and
knockout MEF cultures was monitored and recorded in real time during treatment with indicated concentrations of 5-FU. Shown are mean percentages
of confluence at the respective time points with error bars representing standard deviations (SD) of three independent cultures.
(B) HeLa cells overexpressing TDG show increased sensitivity towards 5-FU, whereas siRNA-mediated TDG knockdown results in increased 5-FU
resistance. Shown is the clonogenic survival of HeLa cells with different TDG expression levels following treatment with 5-FU for 72 h (left). Data points
represent percentages of colony-forming units (5-FU/mock; mean 6 SEM) from at least three independent experiments. Corresponding TDG protein
levels 72 h after plating of the cells are shown in the right panel. TDG was detected with a monoclonal anti-human TDG antibody (TDGmab) in extracts of
cells treated with siRNA directed against TDG, or a corresponding siRNA control.
pC, vector control; pTdg, Tdg expressing vector; T#, Tdg siRNA; C#, control siRNA.
doi:10.1371/journal.pbio.1000091.g002
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phase when UNG2 is down-regulated [33–35], TDG consti-
tutes a major and rate-limiting A5-FU–processing activity.
This is consistent with measurements of 5-FU incorpora-
tion into genomic DNA following 5-FU treatment. The
genomic levels of uracil and 5-FU upon treatment with 10
lM 5-FU for 48 h were four and 11 times higher in TDG
knockout MEFs (3.43 105 U residues; 1.73 106 5-FU residues)
than in wild-type cells (8.2 3 104 U residues; 1.5 3 105 5-FU
residues), respectively, and this compares to the levels
measured in 5-FU–treated Smug1 knockdown cells (D. Barnes,
personal correspondence; [9]). Not only do these data conﬁrm
that 5-FdUMP gets incorporated into genomic DNA, they also
establish that both TDG and Smug1 constitute the major
activities processing these lesions, whereas UNG2 does not
appear to contribute signiﬁcantly as also implicated by uracil/
5-FU incorporation measurements and sensitivity tests with
Ung/ knockout cells [9,15].
5-FU Treatment Induces TDG-Dependent DNA Strand
Breaks
5-FU treatment has been associated with the generation of
DNA strand breaks [2,10,11]. In the light of our biochemical
evidence, implicating TDG in processing genomic A5-FU
base pairs, this might be accounted for by an accumulation of
apyrimidinic/apurinic sites (AP-sites) in DNA. Through
further processing by the BER system, spontaneous breakage,
or stalling of DNA polymerases, these could give rise to
increased levels of single-stranded DNA breaks (SSBs) in cells.
To test this hypothesis, we applied alkaline Comet analyses to
assess 5-FU–induced SSB formation in TDG-proﬁcient and
-deﬁcient MEFs, as well as in complemented knockout cells
stably expressing an ectopic wild-type or catalytic mutant Tdg
(Figure 4A). To avoid Tdg overexpression artifacts in the
latter [33], we made use of constructs that drive Tdg
expression from its endogenous promoter (D. Schuermann,
unpublished results). Automated analyses of Comet tail
moments then showed similar background levels of DNA
strand breaks in all untreated cell populations. Following
treatment with 5 lM 5-FU for 24 h and a recovery of another
24 h, however, the tail moments increased signiﬁcantly above
background in TDG-proﬁcient populations, whereas no
signiﬁcant increase was detected for TDG-deﬁcient cells
(Figure 4B). Remarkably, cells complemented with the
catalytic-inactive mutant form of TDG did not show
signiﬁcantly elevated tail moments after 5-FU treatment.
These data indicate that base excision by TDG accounts for
the increase in steady-state levels of DNA strand breaks
observed upon treatment of cells with 5-FU.
DNA processing after base excision generates SSBs, feeding
into a SSB repair pathway whereby XRCC1 plays a central
role [36]. To address a possible engagement of SSB repair
following 5-FU treatment, we quantiﬁed nuclear XRCC1 foci
by immunoﬂuorescence detection of the endogenous protein
with speciﬁc mono- and polyclonal antibodies [37]. This
showed indeed that the median number of XRCC1 foci per
cell increased after 24 h of low-dose 5-FU treatment and a
Figure 3. Involvement of TDG in Processing of Uracil and 5-FU
(A) Base release activities of purified recombinant mouse TDG (mTDG)
and nuclear protein extracts of TDG wild-type (Tdgþ/þ), heterozygous
(Tdgþ/), and knockout (Tdg/) MEFs on uracil, 5-FU, and GT containing
synthetic 60-mer DNA duplexes. Shown are representative results of base
release assays with the intact substrate DNA strands (S) and the cleaved
products (P) resolved on denaturing polyacrylamide gels. All reactions
were performed in the presence of the UNG inhibitory UGI peptide.
Purified TDG processes thymine, uracil, and 5-FU when opposite guanine
as well as 5-FU paired with adenine, but only inefficiently uracil opposite
adenine.
(B) Quantitation of base release activities in nuclear extracts. GT
processing activity is reduced in protein extracts of heterozygous cells
and absent from knockout extracts. Tdg knockout extracts also show a
significant reduction of A5-FU processing. All other uracil- and 5-FU–
containing substrates were processed with similar efficiencies by all three
nuclear extracts. Data are presented as means 6 SD from three
independent experiments.
An asterisk (*) indicates the 5’-fluorescein-labeled strand.
doi:10.1371/journal.pbio.1000091.g003
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recovery of 24 h in the absence of the drug (Figure 4C). We
therefore conclude that uracil/5-FU excision from genomic
DNA activates SSB repair processes at the site of the lesion.
Remarkably, 5-FU treatment induced signiﬁcantly more
XRCC1 foci in Tdg knockout cells, indicating higher SSB
repair activity in these cells, most probably downstream of
uracil/5-FU excision by the remaining UDG activities. Thus,
in wild-type cells TDG may compete with these glycosylases
for the 5-FU substrates, generate AP-sites, but then prevent
efﬁcient downstream processing of the repair intermediates
by the SSB repair pathway.
5-FU Arrests MEFs in S-Phase and Activates DNA Damage
Responses
5-FU treatment was shown to delay or even arrest S-phase
progression in HeLa and DT40 cells [38,39]. To address the
role of TDG in this context, we determined the cell-cycle
proﬁles of TDG-proﬁcient and -deﬁcient MEFs following 5-
FU treatment. Relative to the mock control, treatment for 24
h with 5 lM 5-FU and subsequent cultivation in drug-free
medium for additional 24 h resulted in a signiﬁcant enrich-
ment of Tdg wild-type cells in the S (2-fold) and G2/M phases
(1.3-fold) of the cell cycle (Figure 5A). This enrichment
occurred at the expense of the G1 cell population, which was
reduced by a factor of three. By contrast, the 5-FU–induced
changes in cell-cycle distribution of TDG-deﬁcient MEFs were
less pronounced and not statistically signiﬁcant (Figure 5A).
Since a treatment with hydroxyurea (HU) impeded S-phase
progression equally in both cell lines (unpublished data), a
defective intra–S-phase DNA-damage checkpoint in the TDG
knockout MEFs can be excluded. To corroborate the TDG
dependence of the 5-FU–mediated S-phase delay, we com-
pared the response of Tdg knockout cells complemented by
stable expression of endogenous levels of wild-type Tdg with
that of a vector control. Also in this setting, the S-phase delay
Figure 4. 5-FU–Induced DNA Strand Breaks Are Reduced in TDG-Deficient Cells whereas Overall Repair Activity Is Increased.
(A) Complementation of Tdg knockout MEFs with wild-type and catalytically deficient TDG. Stable transfectants of Tdg/MEFs ectopically expressing
either TDG variant from the native promoter show TDG levels about the same as endogenous, as detected by western blotting.
(B) Reduced levels of 5-FU–induced DNA strand breaks in cells lacking active TDG. Steady-state levels of DNA single- and double-strand breaks in the
cell lines indicated were assessed by the alkaline Comet assay using automated comet tail moment analysis. 5-FU treatment results in a significant tail
moment increase in wild-type, but not in Tdg knockout MEFs. The generation of 5-FU–specific DNA strand breaks in Tdg knockout cells is restored by
complementation with wild-type Tdg, but not with the catalytically inactive mutant. Shown are box plots with individual tail moments per cell, medians,
interquartile ranges (boxes), 2.5%–97.5% percentiles (whiskers) and outliers (dots) of pooled data (600 to 900 cells) obtained from three independent
experiments.
(C) 5-FU treatment triggers DNA SSB repair in TDG wild-type and knockout cells. The top panel shows nuclei of Tdg-proficient and -deficient cells
stained with a polyclonal anti-XRCC1 antibody (XRCC1ab) after 5-FU treatment. The statistical analysis of XRCC1 foci per cell across the populations
analyzed (n  100 cells per population) is shown as a scatter plot with medians and the interquartile ranges.
pC, empty vector; pTdg, vector expressing TDG; pTdgcat, vector expressing a catalytic dead variant.
doi:10.1371/journal.pbio.1000091.g004
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induced by 5-FU treatment was signiﬁcantly more pro-
nounced in the Tdg-expressing cell line (1.7-fold vs. 1.2-fold)
(Figure 5B). Thus, TDG contributes to cell-cycle responses
following 5-FU treatment.
5-FU–induced cell-cycle arrest in early S-phase was shown
previously to depend on Chk1, an effector protein kinase
[38,39] that gets activated in response to DNA damage or
replication stress through ATR-dependent serine (S317 and
S345) phosphorylation (Chk1-p) [40]. We examined the role
of TDG in checkpoint activation following treatment of cells
with 10 lM 5-FU for 24 h and a recovery in drug-free medium
for another 24 h. Immunoblotting of whole-cell extracts with
a S345 phospho-speciﬁc Chk1 antibody conﬁrmed signiﬁcant
activation of the kinase in Tdg wild-type cells (Figure 6A). In
extracts of 5-FU–treated Tdg knockout cells, however, 5-FU–
induced Chk1 phosphorylation was hardly detectable. This
was not due to an absence of Chk1 or an inability to
phosphorylate the kinase in these cells; immunodetection of
total Chk1 protein conﬁrmed similar levels in wild-type and
knockout extracts (Figure 6A), and the replication inhibitor
HU induced Chk1 phosphorylation in both cell types (Figure
6C). Note that the reduced TDG protein levels detected in the
extracts of 5-FU treated wild-type MEFs (Figure 6A) reﬂect
the accumulation of the cells in S-phase, where TDG is not
expressed [33]. Finally, stable transfection of a TDG-express-
ing plasmid restored 5-FU–inducible Chk1 phosphorylation
in the Tdg knockout cells (Figure 6B).
To address the dynamics of Chk1 activation, we monitored
S345 phosphorylation during a 24-h treatment with 10 lM 5-
FU and an additional recovery time of 24 h in the absence of
5-FU. Weak Chk1 phosphorylation became detectable after
16 h of treatment both in Tdg wild-type and knockout MEFs.
This initial signal persisted throughout a treatment period of
24 h (Figure 6C), but declined gradually during the
subsequent recovery period. Strikingly, however, in TDG-
proﬁcient cells, Chk1 phosphorylation reappeared at 40 h
into the time course, which is 16 h after removal of the drug
(Figure 6C). Thus, 5-FU elicits an early checkpoint response
that is independent of TDG and a late response that depends
on TDG.
Another readout of ATM- or ATR-dependent DNA-
damage responses is the formation of nuclear foci containing
a phosphorylated variant of histone H2AX [41]. cH2AX is
considered a marker of DNA damage, including DNA double-
strand breaks that may occur during DNA replication when
moving forks encounter damage in the parental strands. We
thus measured changes in the steady-state levels of cH2AX
foci in TDG-proﬁcient and -deﬁcient MEF populations upon
treatment with 5 lM 5-FU for 24 h and additional recovery
for 24 h in drug-free medium. Although both mock-treated
cell lines showed similar levels of cH2AX foci, the wild-type
MEFs accumulated signiﬁcantly higher numbers of cH2AX
foci than the TDG-deﬁcient cells during 5-FU treatment
(Figure 6D). This corroborates that 5-FU treatment induces
DNA strand breaks and, consequently, DNA-damage signaling
in a TDG-dependent manner.
Discussion
Despite many years of clinical application, the mode of
action underlying the therapeutic efﬁcacy of the antimeta-
bolite 5-FU has remained elusive. Circumstantial evidence,
however, has suggested that a signiﬁcant part of its cancer-
directed cytotoxicity is mediated through the excision of
misincorporated uracil or 5-FU from genomic DNA, saturat-
ing the cellular SSB repair capacity [2]. Such a scenario
Figure 5. 5-FU Treatment Induces a TDG-Dependent S-Phase Delay
The histograms show the effect of the 5-FU treatment on the relative
cell-cycle distribution (% cells) of TDG-proficient and -deficient MEFs (A),
and of TDG knockout cell lines stably transfected with a plasmid
expressing Tdg from its authentic promoter (B). 5-FU treatment of TDG-
proficient cells results in a significant accumulation cells in S-phase at the
expense of G1 cells, whereas TDG-deficient cells show only insignificant
changes in cell-cycle distribution. Expression of wild-type Tdg in
knockout MEFs partially restored the 5-FU–dependent S-phase delay.
The data shown represent averages of three independent experiments
with fold changes upon 5-FU treatment.
pC, empty vector; pTdg, vector expressing TDG.
doi:10.1371/journal.pbio.1000091.g005
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clearly implicates a critical role for UDGs in mediating the
cytotoxicity. However, Smug1 was reported to protect cells
from the cytotoxic effects of 5-FU, and the status of UNG2,
the catalytically most efﬁcient UDG of all, does not seem to
affect cellular sensitivity [9,14,15]. MBD4-deﬁcient cells were
shown to have a survival beneﬁt on 5-FU [20], but this may
not be linked to the loss of DNA glycosylase activity since
immunodepletion of the enzyme did not alter the 5-FU repair
capacity of nuclear extracts [24]. Thus, whether or not and to
what extent UDG activities are responsible for the DNA
directed 5-FU toxicity remained unclear.
Our data now establish a signiﬁcant contribution of TDG
to DNA-directed 5-FU cytotoxicity. We show that inactivation
of Tdg in MEFs, but also in ES cells, results in a marked
Figure 6. TDG-Dependent Activation of DNA Damage Responses upon 5-FU Treatment
(A–C) TDG mediates late Chk1 activation following 5-FU treatment. Activation of Chk1 in TDG-proficient and -deficient MEFs (A) as well as in
complemented knockout cells (B) was determined by western blotting with a S345 phospho-specific antibody against Chk1 (Chk1-Pab). After treatment
with 10 lM 5-FU, wild-type but not TDG-deficient MEFs show a strong accumulation of S345 phosphorylated Chk1. Total Chk1 protein is the same in
both MEF lines before and after 5-FU treatment (Chk1ab). TDG levels in wild-type cells, detected with a specific anti-mTDG antibody (TDGab), are reduced
in 5-FU–exposed cells, reflecting an accumulation of cells in S-phase, where TDG is absent. Tdg knockout MEFs stably expressing an ectopic copy of Tdg
(B) contain low levels of TDG, which is sufficient to induce Chk1 activation upon 5-FU treatment.
(C) Dynamics of Chk1 activation in TDG-proficient and -deficient MEFs during and after exposure to 5-FU or HU. The 5-FU–containing (10 lM) or HU-
containing (2.5 mM) medium was replaced with drug-free medium after 24 or 16 h, respectively. Samples were taken at the time points indicated and
analyzed for Chk1 S345 phosphorylation by western blotting. After 16 h into treatment, activated Chk1 appears equally in extracts from 5-FU– and HU-
treated cells; at 24 h, the Chk1-p signal is undetectable in the HU-treated samples and significantly reduced in 5-FU–treated cells; at 40 h, significant
levels of phosphorylated Chk1 reappear in 5-FU–exposed TDG-proficient MEFs but not in TDG-deficient MEFs.
(D) The induction of cH2AX foci by 5-FU treatment is significantly reduced in TDG-deficient MEFs. The top panels show examples of MEFs
immunostained with a monoclonal antibody against cH2AX (cH2AX mab) after treatment with 5 lM 5-FU. The statistical analysis of cH2AX foci per cell
across the populations analyzed (n . 95 cells per population) is depicted in the lower panel as scatter plot with medians and the interquartile ranges.
pC, empty vector; pTdg, vector expressing TDG; TDG-S, TDG modified with SUMO. An asterisk (*) indicates an unspecific cross-reaction of the secondary
antibody
doi:10.1371/journal.pbio.1000091.g006
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cellular resistance towards 5-FU, which can be complemented
by expression of wild-type Tdg. The same inverse correlation
between TDG proﬁciency and 5-FU sensitivity was observed
with the human cancer cell line HeLa; TDG overexpression in
HeLa cells increased cellular sensitivity to 5-FU treatment,
whereas siRNA-mediated TDG knockdown in the same cells
provided resistance. This phenotype is apparently speciﬁc to
5-FU as the TDG-deﬁcient MEFs showed no resistance when
treated with MMS. Recently, An et al. [9] demonstrated the
accumulation of appreciable amounts of FdUMP in genomic
DNA following 5-FU treatment of cells, and further presented
genetic evidence consistent with 5-FU rather than uracil in
DNA being the toxic lesion. Our data show that nuclear
extracts from TDG-deﬁcient cells excise 5-FU from A5-FU
base pairs with signiﬁcantly reduced efﬁciency when com-
pared to wild-type extracts. Although this difference is
detectable only upon inhibition of the highly active UNG2
by the UGI peptide, it nevertheless implicates a rate-limiting
contribution of TDG to the excision of 5-FU in non–S-phase
cells, where UNG2 activity is down-regulated [33–35]. In
agreement with this, we found TDG-deﬁcient MEFs to
accumulate signiﬁcantly higher levels of 5-FU in their DNA
than TDG-proﬁcient cells following 5-FU exposure. Hence,
TDG processes 5-FU in genomic DNA and may thus
contribute to the cytotoxicity of the drug. Given the inability
of TDG to excise U from the AU base pair on the one hand
[21,22], and the comparably high contribution of TDG to
A5-FU processing in nuclear extracts on the other hand, we
argue that the primary TDG relevant cytotoxic DNA lesion is
the A5-FU base pair.
Consistent with a concept of DNA repair generating lethal
DNA strand breaks upon 5-FU treatment [2], our Comet data
show an increase of the tail moment in 5-FU–treated MEFs,
and this effect is largely dependent on the presence of a
catalytically active TDG. At the same time, we observed a
signiﬁcant increase of the number of XRCC1 foci per cell,
suggesting that 5-FU treatment triggers DNA SSB repair [36].
Strikingly, after 5-FU treatment, Tdg knockout cells produced
signiﬁcantly higher levels of XRCC1 foci than their wild-type
counterparts, suggesting that the loss of TDG enhances
overall SSB repair activity while reducing lethal 5-FU
processing.
Why then is the excision of 5-FU (or uracil) by TDG
cytotoxic, whereas excision by other UDGs, particularly
Smug1, protects against cell death [9]? The difference may
relate to the distinct modes of action of these enzymes. Both
TDG and Smug1 bind AP-sites in DNA, albeit with different
afﬁnities. The dissociation of the glycosylases from these
repair intermediates is therefore rate limiting for further
processing [23,42]. However, whereas Smug1 can be made to
turnover in the presence of APE1, the downstream-acting
endonuclease competing for the AP-site [42], efﬁcient AP-site
release (and stimulation by APE1) of TDG requires a SUMO
modiﬁcation–induced conformational change that reduces
its DNA binding afﬁnity [43,44]. Thus, base excision by Smug1
may connect to a straightforward downstream repair process,
whereas base excision by TDG may be associated with delayed
repair of the AP-site, possibly due to saturation of the
SUMOylation system. Some AP-sites generated by TDG would
thus escape repair until they eventually interfere with DNA
replication, leading to fork stalling and collapse, and
activation of replication stress or DNA-damage checkpoints
[45]. Indeed, we and others found 5-FU treatment to affect
the progression of cells through S-phase [39,46], and this
effect was associated with activation of the Chk1 kinase that
contributes to S and G2/M checkpoints [47]. Both an
accumulation of cells in S-phase and the activation Chk1
upon 5-FU exposure were virtually absent in TDG-deﬁcient
MEFs, and were in line with reduced levels of 5-FU–induced
DNA strand breaks and cH2AX foci in these cells.
We reported previously that TDG is absent from S-phase
cells due to programmed degradation by the proteasome
system at the G1–S boundary [33]. This is consistent with the
dynamics of Chk1 activation and cell death in our experi-
ments, both indicating that the TDG-dependent cytotoxic
action is temporally separated from the incorporation of 5-
FU (and U) into DNA. On the basis of these ﬁndings, we can
now put forward a model for how temporally separated 5-FU/
uracil misincorporation and repair processes can determine
the cellular responses to 5-FU (Figure 7). Upon exposure to 5-
FU, 5-FU/uracil will be misincorporated into DNA during
DNA replication in S-phase of the cell cycle. In this context,
UNG2 will act efﬁciently on uracil (AU and GU) but less so
on 5-FU [9], whereas Smug1 (and MBD4) may process the
same lesions but with lower efﬁciencies. These repair events
will activate the ﬁrst wave of checkpoint responses that is
TDG independent. Due to saturation of uracil repair,
considerable amounts of A5-FU base pairs will persist in
the DNA into the subsequent phases of the cell cycle, where
UNG2 is down-regulated, and they will be attacked mainly by
TDG and Smug1. AP-sites generated by TDG will be
protected from repair due to rate-limiting dissociation of
the glycosylase and, hence, accumulate and interfere with the
replication machinery in the subsequent S-phase. This will
give rise to a second wave of checkpoint activation (Chk1
phosphorylation and formation of cH2AX), this time TDG
dependent, which is correlated with the occurrence of DNA
strand breaks, even if the cells are no longer cultivated in the
presence of 5-FU.
Notably, according to a recent report, breast cancer
patients carrying a speciﬁc polymorphism in XRCC1 have a
signiﬁcantly reduced risk of recurrence and show better long
time survival following a combination therapy with cyclo-
phosphamide–methotrexate–5-FU [48]. The same polymor-
phism was previously reported to reduce DNA repair activity
of XRCC1 [48,49], suggesting that inactivation of DNA SSB
repair can improve the efﬁcacy of 5-FU treatment. The data
presented here for TDG, and previously for Smug1 [9], are
consistent with 5-FU excision being responsible for the
generation of a signiﬁcant fraction of AP-sites and DNA
SSBs following 5-FU treatment. It is now becoming clear that
the efﬁciency of coupling downstream repair with base
excision, presumably through XRCC1, depends on the
biochemical properties of the DNA glycosylase engaged and
critically determines the cellular responses to the drug. It will
therefore be important to examine to what extent the status
of TDG activity correlates with the response of tumors to 5-
FU–based chemotherapy.
Materials and Methods
Reagents, antibodies, and Tdg expression constructs. Chemicals
and reagents were purchased from Sigma, Complete protease
inhibitor from Roche, RNase from Qiagen and UGI from New
England Biolabs. LIF was from Chemicon-Millipore, sodium pyruvate
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from Invitrogen, and all other supplements or cell culture media
from Sigma. The polyclonal rabbit anti-mTDG antiserum was newly
generated by immunization with recombinant full-length mouse
TDGa (Primm Labs). Rabbit anti-Chk1 (#2345) and rabbit anti-Chk1-
Ser345p (#2341) antibodies were from Cell Signaling, the mouse anti–
b-actin (ab8226) antibody was from Abcam, the rabbit anti-XRCC1
(X0629) was from Sigma, and the mouse anti-cH2AX (#05–636) was
from Chemicon-Millipore. The monoclonal rat anti-hsTDG antibody
was described in [44]. The secondary horseradish peroxidase–
conjugated antibodies against mouse (NXA931) or rabbit (NA934V)
were purchased from GE Healthcare Life Sciences, the secondary
Cy2-conjugated donkey anti-mouse IgG (715-225-151) and anti-rabbit
IgG (711-225-152) antibodies, and donkey serum (017-000-001) were
from Jackson ImmunoResearch Laboratories, and the horseradish
peroxidase–conjugated antibody against rat (A5795) was from Sigma.
ON-TARGETplus SMARTpool siRNA against human Tdg (L-003780–
01), ON-TARGETplus Non-targeting Pool control siRNA (D-001810–
10) and DharmaFECT siRNA transfection reagent (T-2001) were from
Thermo Scientiﬁc Dharmacon.
For bacterial expression of an N-terminally 6xHis-tagged mouse
TDG, the murine TdgA cDNA (GenBank accession number:
NM_172552) was cloned into pET28c (Novagen-Merck). Mammalian
expression constructs were obtained by PCR cloning of the mouse
TdgA sequence into pSG5-HH25 [44] or pTCO4 (D. Schuermann,
unpublished data) for expression controlled by the SV40 or the
authentic Tdg promoter, respectively. Constructs expressing human
Tdg from a CMV promoter were obtained by PCR cloning of the Tdg
cDNA (GenBank: NM_003211) into pCEP4 (Invitrogen). In vitro
mutagenesis of mouse Tdg was performed using the QuikChange site-
directed mutagenesis kit (Stratagene). PCR primer sequences and
vector maps are available on request.
Cell culturing. For spontaneous immortalization, primary cells
from Tdg/ embryos (ED 9.5) were expanded in growth medium
(DMEM, 10% FCS, 2 mM L-glutamine). Cultures were kept at ,90%
conﬂuency at all times. Spontaneously immortalized cell lines were
obtained through prolonged cultivation in medium containing 20%
FCS and stored in growth medium containing 10% DMSO at 53 106
cells/ml in liquid nitrogen. Alternatively, primary cells were immor-
talized by transfection with a plasmid expressing SV40 large T-
antigen. Immortal MEFs were cultivated in growth medium contain-
ing penicillin/streptomycin (pen/strep) at 37 8C with 5% CO2. For
complementation, Tdg/ cell lines were transfected at 70% conﬂu-
ency with 1 lg of plasmid DNA and the Transfectin reagent (BioRad).
Puromycin-resistant cells were selected and further maintained in
medium supplemented with 1.5 lg/ml puromycin. For protein
extraction, Comet assays or FACS analysis, 1 3 106 (mock) or 2 3
106 (5-FU) cells were seeded into 10-cm culture dishes and incubated
for 24 h. Cells were treated with indicated 5-FU concentrations for 24
h and washed with PBS. After additional incubation for 24 h in drug-
free medium, cells were harvested by trypsinization. Mouse ES cells
with a homozygous disruption of the Tdg gene were selected with
increasing concentrations of neomycin from ES cells heterozygous
for Tdg. ES cells were passaged in ES medium (DMEM, 15% heat-
inactivated FCS, 2 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1
mM sodium pyruvate, 13 nonessential amino acids, 13 pen/strep,
1,000 U/ml LIF) in the presence of c-ray–inactivated feeder cells,
which were removed prior to sensitivity assays. HeLa cells were
maintained in growth medium containing penicillin/streptomycin
(pen/strep) at 37 8C with 5% CO2.
Protein extraction and western blotting. Cells were washed with
ice-cold PBS and lysed for 30 min on ice in lysis buffer (50 mM Na-
phosphate [pH 8.0], 125 mM NaCl, 1% NP-40, 0.5 mM EDTA, 1 mM
PMSF, 1 mM DTT, 13 Complete protease inhibitors, 23 phosphatase
inhibitor cocktail 1 and 2). Extracts were clariﬁed by centrifugation
(15 min, 20,000g, 4 8C). Protein concentrations were determined using
the Bradford reagent (BioRad). A total of 50 lg of soluble protein was
separated in 10% SDS-polyacrylamide gels and transferred to a
nitrocellulose membrane (Millipore). Membranes were washed once
with TBS-T (100 mM Tris/HCl [pH 8.0], 150 mM NaCl, 0.1% Tween20)
and incubated with blocking buffer (TBS-T, 5% dry milk) for 1 h at
room temperature (RT). Blocked membranes were washed once with
TBS-T for 5 min before incubation with the primary antibody for 1 h
at 33 8C (anti-mTDG) or RT (anti–b-actin) in blocking buffer or
overnight at 4 8C in TBS-T containing 5% BSA (anti-Chk1 and anti-
Chk1-Ser345p). Dilutions were: 1:10,000 for the rabbit anti-mTDG
antibody and the mouse anti-b-actin, 1:1,000 for the rabbit anti-Chk1
and the rabbit anti-Chk1-Ser345p. The washing steps after hybrid-
ization were: once at 33 8C and twice at RT for 15 min (anti-mTDG),
three times at RT for 10 min (anti-b-actin), and three times for 5 min
at RT (anti-Chk1 and anti-Chk1-Ser345p). Both secondary horse-
radish peroxidase–conjugated antibodies were diluted 1:5,000 in
blocking buffer and hybridized to the membranes for 1 h at RT. After
three washing steps of 10 min at RT, detection of the signals was
carried out using the Immobilon Western Chemiluminescent HRP
Substrate (Millipore).
Cell-sensitivity assays. Cell viability of MEFs and ES cells was
measured by the Cell Counting Kit-8 (Dojindo). Triplicate cultures of
each cell line were plated in 96-well plates at 13103 cells per well and
pre-incubated in the respective growth medium. 5-FU or MMS was
added to ﬁnal concentrations as indicated. Cells were exposed for 48
h to 5-FU (MMS: 1 h, and an additional 47 h in normal growth
medium), and then washed with PBS before incubation in medium
containing the WST-8 substrate at 37 8C. After incubation for 2 h
(MEF) or 4 h (ES), the cell density was measured indirectly by
quantiﬁcation of the solubilized formazan product at 450 nm with a
SpectraMax340 microplate spectrophotometer (Molecular Devices).
For real-time analysis of cell growth during 5-FU treatment, MEF cells
were seeded in 12-well plates at approximately 5% conﬂuence.
Following a preincubation of 24 h, the growth medium was
exchanged with medium containing 5-FU concentrations as indi-
cated. Cell proliferation was recorded with an automated IncuCyte
microscope (Essen Instruments) by monitoring nine regions per well
every hour. The assessment of cell proliferation was based on
conﬂuence as calculated by the integrated IncuCyte software. For
Figure 7. TDG-Dependent 5-FU Cytotoxicity
Illustrated are the cell-cycle distributions of the three relevant UDGs,
TDG, UNG2, and Smug1 (top), together with expected levels of genomic
5-FU, uracil, AP-sites, and the observed Chk1 activation following 5-FU
treatment (bottom). TDG is present during the G2/M and G1 phases but
is degraded prior to and absent from S-phase. UNG2 shows a strictly
inverse regulation whereas Smug1 is expressed throughout the entire
cell cycle. Treatment with 5-FU for 24 h gives rise to misincorporation of
appreciable levels of 5-FU and uracil during S-phase (S1), resulting in
Chk1 activation by ongoing replication-associated UNG2 and Smug1-
dependent BER. Although Smug1 and UNG2 will initiate faithful repair of
uracil and 5-FU bases directly after DNA synthesis, these pathways will
become saturated under 5-FU exposure and, in addition, are relatively
inefficient in processing the 5-FUA base pairs. Hence, some of them will
persist in the DNA into the subsequent G2 and G1 phases of the cell
cycle. There, TDG will initiate repair, but turnover with a low rate, leading
to an accumulation of AP-sites and/or DNA SSBs. During the subsequent
S-phase, these repair intermediates will interfere with DNA replication,
causing replication fork stalling, fork collapse, DNA double-strand breaks,
and a second round of Chk1 activation. Due to genome fragmentation,
cells will then induce apoptosis.
doi:10.1371/journal.pbio.1000091.g007
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measurement of clonogenic cell survival, HeLa cells were plated at 3
3105/well in six-well plates. After 24 h, cells were transfected with 100
nM siRNA (Tdg-directed or control) using DharmaFECT 1 according
to the manufacturer’s instructions. Twenty-four hours after trans-
fection, cells were trypsinized, counted, and then plated in duplicate
in 10-cm dishes at cell densities between 200 and 800 cells/dish in
growth medium containing 5-FU concentrations as indicated.
Remaining cells were further cultivated in normal growth medium
for Western blot analysis of TDG protein after 72 h. Seventy-two
hours after plating, the medium of 5-FU and mock-treated cells was
exchanged with 5-FU–free growth medium, and plates were incu-
bated for additional 14 d. Colonies were visualized by staining with a
10% Giemsa solution after washing with PBS and ﬁxation with 50%
methanol.
Puriﬁcation of recombinant mTDGa. For expression of mTDGa, 2 l
of Superbroth containing 50 lg/ml kanamycin were inoculated with
an overnight culture of Escherichia coli BL21(DE3) transformed with
pET-28c-mTdgA. The culture was grown to an A600 (absorbance at 600
nm) of 0.6 and cooled to 15 8C. TDG expression was induced by the
addition of 200 lM IPTG and incubation was allowed to proceed at
15 8C for 23 h. Cells were collected by centrifugation (Sorvall SLC-
6000, 5,000 rpm, 4 8C, 30 min), and the pellets were resuspended in 3
ml/g sonication buffer (50 mM Na-phosphate [pH 8.0], 750 mM NaCl,
20% glycerol, 1 mM imidazole, 10 mM b-mercaptoethanol, 1 mM
phenylmethylsulfonyl ﬂuoride). After shock freezing in liquid nitro-
gen, cells were stored at 80 8C. Crude extracts were prepared by
sonication (12 times for 30 s on ice with intermittent chilling), and
clariﬁed by centrifugation (Sorvall SS34, 18,000 rpm, 48 C). All steps
were performed at 4 8C. The supernatant was applied to a disposable
column packed with 1.5 ml of pre-equilibrated Ni-NTA agarose
(Qiagen) at a ﬂow rate of 15 ml/h. After washing with 120 ml of
buffer, bound proteins were eluted with 10 ml of sonication buffer
containing 500 mM imidazole and dialyzed against buffer H50 (50
mM Na-phosphate [pH 8.0], 50 mM NaCl, 20% glycerol, 10 mM b-
mercaptoethanol, 1 mM phenylmethylsulfonyl ﬂuoride). After load-
ing the dialyzed fraction onto a 5-ml HiTrap Heparin HP column (GE
Healthcare) at a ﬂow rate of 1 ml/min and washing with 10 ml of H50,
bound protein was eluted with a liner gradient of 50–800 mM NaCl in
50 ml. Purest fractions were pooled, dialyzed against buffer Q20 (50
mM Na-phosphate [pH 8.5], 20 mM NaCl, 10% glycerol, 10 mM b-
mercaptoethanol, 1 mM phenylmethylsulfonyl ﬂuoride), and loaded
on a 1-ml HiTrap Q HP at a ﬂow rate of 1 ml/min. After washing with
10 ml of Q20 buffer, bound proteins were eluted with a linear
gradient of 20–500 mM NaCl in 15 ml. The fractions containing TDG
with.98% homogeneity were pooled, dialyzed against storage buffer
(50 mM Na-phosphate [pH 8.0], 50 mM NaCl, 10% glycerol, 10 mM b-
mercaptoethanol, 1 mM phenylmethylsulfonyl ﬂuoride), frozen in
liquid nitrogen and stored at 80 8C.
Base release assays and assessment of genomic uracil and 5-FU.
Nuclear protein extracts were prepared according to [33]. For base
release assays, 20 lg of nuclear proteins were incubated with 1 pmol
of a ﬂuorescein-labeled homoduplex or mismatched DNA substrate
(2) in reaction buffer (50 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1 mM
DTT, 1 mg/ml BSA, 2 U UGI) for 20 h at 37 8C. Generated AP-sites
were cleaved by the addition of NaOH to a ﬁnal concentration of 100
mM and heating to 95 8C for 10 min. Subsequently, DNA was ethanol
precipitated overnight at20 8C in 0.3 M Na-acetate (pH 5.2) and in
the presence of 0.4 mg/ml carrier tRNA. The DNA was collected by
centrifugation (20 min, 20,000g, 4 8C) and washed in 80% ethanol.
Air-dried pellets were resuspended in loading buffer (13 TBE, 90%
formamide), heated at 95 8C for 5 min, and then immediately chilled
on ice. Reaction products were separated on 15% denaturing
polyacrylamide gels in 13 TBE. The ﬂuorescein-labeled DNA was
visualized with a Typhoon 9400 (GE Healthcare) and quantiﬁed using
the ImageQuant TL software (GE Healthcare). Levels of genomic
uracil and 5-FU were determined as described in [9] after treatment
of cells with 10 lM 5-FU for 24 h.
Alkaline Comet assays. Comet assays were performed according to
[50] with minor modiﬁcations described by [51]. After treatment, cells
were trypsinized, collected by centrifugation (5 min, 450g, RT), and
then washed with PBS. Ten thousand cells were resuspended in 100 ll
of low-melting-point agarose (PBS, 0.5% LMPA; Lonza) at 37 8C, and
casted onto microscope slides precoated with 1.5% normal melting
agarose (BioRad). After gelling, cells were lysed by immersion of the
slides in freshly prepared ice-cold lysis buffer (2.5 M NaCl, 100 mM
EDTA, 10 mM Tris/HCl [pH 10], 1% TritonX-100, 10% DMSO) for 90
min at 4 8C. Slides were then washed with ddH2O and covered with
fresh electrophoresis buffer in an electrophoresis tank (1 mM EDTA,
300 mM NaOH [pH .13]). After DNA denaturation for 30 min at 4
8C, electrophoresis was performed at 25 V and 300 mA for 20 min. All
the above steps were done under dimmed light. Neutralization was
carried out by three washings of 10 min with 0.4 M Tris/HCl (pH 7.5)
at RT. After two ﬁxation steps of 5 min in 100% EtOH at RT, slides
were air-dried and stained with 50 ll PI solution (Vectashield, 2.5 lg/
ml propidium iodide). Comet tail moments of 100 to 150 cells per
slide were analyzed by automated analysis [52] using a Leitz MIAS
image analyzer (Leitz Messtechnik) together with a Leica DM RBE
microscope (Leica Microsystems).
FACS analysis. A total of 5 3 105 to 5 3 106 cells were ﬁxed
overnight in 5 ml of 70% ethanol at 4 8C, collected by centrifugation
(5 min, 800g, 4 8C) and resuspended in 0.3 ml of RNase solution (100
mM Tris/HCl [pH 7.5], 100 mM NaCl, RNase 0.5 mg/ml). RNA
digestion was performed at 37 8C for 45 min; 0.3 ml of PE solution
(0.4% HCl, pepsin 1 mg/ml) was added to the samples during the last
15 min of incubation. The DNA was stained by the addition of 0.6 ml
PI solution (PBS, 50 lg/ml propidium iodide) on ice for 30 min.
Samples were analyzed by ﬂow cytometry with a FACS Canto ll
cytometer (Beckton Dickinson). Cell-cycle distribution was analyzed
using the FlowJo software (TreeStar).
Immunoﬂuorescence. MEFs were cultivated on coverslips for 24 h.
Cells were then treated with 5 lM 5-FU for 24 h followed by
cultivation in drug-free medium for another 24 h. Coverslips were
then washed twice in PBS and the cells ﬁxed for 15 min with PF-
buffer (PBS, 2% paraformaldehyde) at RT, washed 43 10 min in PBS
at RT, and permeabilized in ice-cold P-buffer (PBS, 0.2% TritonX100)
for 5 min. Coverslips were incubated for another 5 min in ice-cold P-
buffer containing 0.2% NaBH4. After blocking twice in H-buffer for
10 min (PBS, 1% BSA) and once in D-buffer for 10 min (PBS, 1:20
donkey serum), samples were hybridized with the anti-XRCC1 (1:100
dilution in H-buffer) or the anti-cH2AX (1:500 dilution in H-buffer)
antibody for 1 h at RT. Following four washes of 10 min in H-buffer,
the samples were hybridized with the respective Cy2-conjugated
secondary antibody at a dilution of 1:500 (XRCC1) or 1:200 (cH2AX)
in H-buffer for 1 h at RT. After four washes of 10 min in PBS, the
coverslips were dried and embedded in Mowiol (Calbiochem,
Germany). XRCC1 or cH2AX signals were visualized on an Axiovert
200M microscope (Zeiss) using a FITC ﬁlter (excitation 492 nm,
emission 520 nm).
Statistical analysis. Statistical analyses were done using the Prism 5
software (GraphPad Software). Comet tail moment data were
analyzed according to P. Duez et al., 2003 [53] by two-way ANOVA
of medians and 75% percentiles obtained from three independent
experiments, followed by the Bonferroni post test. XRCC1 and
cH2AX foci distributions were tested for normality by the Shapiro-
Wilk test and further evaluated by one-way ANOVA using the
nonparametric Kruskal-Wallis test followed by the Dunn multiple
comparison analysis comparing treated with untreated samples.
Analysis of cell-cycle data was done by the Fisher exact test from
contingency tables comparing the distributions of G1-, S-, and G2-
phase cells.
Supporting Information
Figure S1. Gene Targeting of mTdg on Chromosome 10
The targeting construct was generated by replacement of exons 6 and
7 with a neomycin resistance cassette. This was achieved by the
substitution of a NarI-PacI fragment with the resistance cassette in a
subcloned genomic region spanning from intron 4 to the 39 UTR. In
addition, the targeting construct contained a thymidine kinase (TK)
cassette for negative selection. Arrowheads show the position of
primers used for multiplex-PCR genotyping. The expected length of
PCR products are 1.2 kb and 1.5 kb for the wild-type (wt) and the
targeted loci, respectively. The lower panel shows a typical result
from genotyping of wt (þ/þ), heterozygous (þ/), and null (/) Tdg
MEF.
Found at doi:10.1371/journal.pbio.1000091.sg001 (619 KB TIF).
Figure S2. MEFs Heterozygous for TDG Display an Intermediate Fu
Sensitivity
The sensitivity of TDGþ/þ, TDGþ/, and TDG/cell lines to increasing
amounts of 5-FU was measured after a continuous treatment of 48 h.
The panel shows cell survival as percentage of untreated cells
averaged from three independent experiments. When compared to
wt MEF, cells carrying a homozygous disruption of the TDG gene
were resistant to 5-FU treatment. The sensitivity of a cell line with
heterozygous TDG genotype was in between the sensitivities
measured for wt and knockout MEF. Error bars represent standard
deviations.
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Found at doi:10.1371/journal.pbio.1000091.sg002 (240 KB TIF).
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